Intensive BP Lowering Fails to Cut Cardiovascular Events in Type 2 Diabetes

New late-breaking research presented at the American Heart Association’s Scientific Sessions 2026 in Chicago suggests that intensively lowering systolic blood pressure below 120 mm Hg in middle-aged adults with Type 2 diabetes does not significantly reduce the incidence of cardiovascular death, stroke, heart attack, or other cardiovascular events compared to standard treatment targeting below 140 mm Hg. The OPTIMAL-DIABETES trial, led by Dr. Karla Santo of Einstein Hospital Israelita in São Paulo, Brazil, enrolled more than 9,000 adults aged 50 and older with Type 2 diabetes and elevated blood pressure across 33 sites in Brazil. Participants were randomized to intensive or standard blood pressure treatment and followed for a median of four years. The primary composite outcome occurred in 6.0% of the intensive group versus 6.7% of the standard group—a 10% relative risk reduction that was not statistically significant. However, the intensive group experienced a 55% higher rate of kidney-related events, primarily declines in kidney function, though end-stage renal disease rates were similar between groups.

“These findings add important evidence about optimal blood pressure targets for adults with Type 2 diabetes,” said Santo. She noted that more intensive treatment may still offer modest yet meaningful health benefits. Dr. Otavio Berwanger, chair of the trial’s steering committee, emphasized that the results should not be interpreted as evidence that intensive lowering is ineffective; rather, any cardiovascular benefit may be smaller than in people without diabetes. He stressed that blood pressure management for people with Type 2 diabetes should remain individualized, balancing potential cardiovascular benefits, kidney effects, treatment burden, and patient preferences. The trial was simultaneously published in the New England Journal of Medicine.

The study has limitations, including its open-label design and limited generalizability beyond Brazil. The American Heart Association notes that high blood pressure is the leading preventable risk factor for cardiovascular disease, and its 2025 guideline recommends a target below 130/80 mm Hg, with consideration of below 120 mm Hg for those at increased cardiovascular risk. These findings underscore the need to consider the totality of evidence when defining optimal blood pressure targets for patients with Type 2 diabetes.